# embecta

> embecta manufactures pen needles, insulin syringes and safety injection devices used by roughly 30 million people across more than 100 countries. Spun off from BD in 2022, the New Jersey company is expanding into pharmaceutical drug-delivery platforms following its 2026 acquisition of Owen Mumford.

- **Founded:** 2021
- **Headquarters:** Parsippany, United States
- **Products:** Nano 2nd Gen Pen Needles, Ultra-Fine pen needles and insulin syringes, Safety injection devices, Injection Lab, Aidaptus auto-injector platform
- **Notable:** Completed BD spinoff and Nasdaq listing under EMBC on April 1, 2022., At its 2022 launch, reported production of approximately 8 billion injection devices annually., Inherited injection portfolio serves an estimated 30 million people in more than 100 countries.

## Products & services

- **Nano 2nd Gen Pen Needles** — 4 mm, 32G pen needles with a contoured base, five-bevel tip and ultra-thin wall; sold in multiple pack configurations, including a five-count pack for once-weekly injections.
- **Ultra-Fine pen needles and insulin syringes** — Single-use injection supplies in multiple sizes for people who administer insulin. Product names and availability vary by country.
- **Safety injection devices** — Safety pen needles and syringes for healthcare settings, designed to help protect users against needlestick injuries.
- **Injection Lab** — Online injection education, technique lessons, resource videos and pen-needle information.
- **Aidaptus auto-injector platform** — Drug-delivery platform added through the completed Owen Mumford acquisition, intended to support pharmaceutical partners across therapeutic areas.
- **Insulin patch pump program (discontinued)** — 300-unit disposable insulin delivery system received FDA clearance in August 2024, announced September 3; embecta announced the program’s discontinuation in November 2024 and abandoned commercialization plans.

## Achievements

- Completed BD spinoff and Nasdaq listing under EMBC on April 1, 2022.
- At its 2022 launch, reported production of approximately 8 billion injection devices annually.
- Inherited injection portfolio serves an estimated 30 million people in more than 100 countries.
- Received FDA 510(k) clearance for its insulin delivery system in August 2024, before discontinuing the program.
- Generated approximately US$182 million of free cash flow in fiscal 2025, compared with approximately US$20 million in fiscal 2024.
- Completed the Owen Mumford acquisition in May 2026.

## Latest updates

- **2026-08** — August 31: announced September participation in Wells Fargo and J.P. Morgan investor events.
- **2026-08** — August 7: reported fiscal Q3 revenue of US$271.7 million, down 8.1% year over year; reported generic GLP-1 partner launches in Canada and Brazil with co-packaged needles.
- **2026-05** — May 15: completed acquisition of Owen Mumford, expanding into drug-delivery platforms and broader chronic-care devices.
- **2026-03** — March 19: agreed to acquire Owen Mumford for £100 million upfront and up to £50 million contingent consideration.
- **2026-02** — February 11: Dev Kurdikar became chairman; Claire Pomeroy became lead independent director.

## Links

- Website: https://www.embecta.com/
- LinkedIn: https://www.linkedin.com/company/embecta
- Twitter/X: https://www.twitter.com/embecta
- YouTube: https://www.youtube.com/channel/UCb63AOBkVneTHxg83a1OMVQ
- Instagram: https://www.instagram.com/embecta/
- Facebook: https://www.facebook.com/embecta

---

Profile page: https://yespress.io/embecta
Published by YesPress — https://yespress.io
Last updated: 2026-10-24